health · HHS-NIH11
Single Source for Continuation of the Integrated Islet Distribution Program U24 (Clinical Trial Not Allowed)
National Institutes of Health · RFA-DK-27-147
35 days left
Award Range
$0 – $2.2M
Total Program Funding
$3.3M
Expected Awards
1
Deadline
September 30, 2026
GRANTQUICK SUMMARYPlain-English Overview
NIH single-source continuation for an established research center — $2.2M award to continue an ongoing integrated research program. Not competitive.
Who Should Apply
Only the currently-funded institution.
Who Should NOT Apply
Everyone else — single-source continuation.
Key Requirements (Plain English)
- •Single-source award $2.2M
- •Continuation only
💡 GrantQuick Tip
Not competitive — continuation of existing award.
Competitiveness: Not applicable — single-source.
What This Grant Funds
This is a NOFO for a Single Source competition that will invite application(s) from eligible organization(s) to apply. Please see Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is announcing its intent to issue a single source cooperative agreement award to Beckman Research Institute/City of Hope for the currently funded Integrated Islet Distribution Program (IIDP) to renew the program and maintain support for its continuing mission to provide the scientific community with important islet resources for diabetes research. The IIDP facilitates the distribution of human islets to biomedical researchers by establishing partnerships with qualified islet isolation facilities to prepare and distribute human islets. Human islets remain an essential resource for diabetes research to advance our understanding of human islet cell biology, and to promote the development of new therapies for the prevention and treatment of diabetes.This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.
Attachments
Who Can Apply
Only the PI/PDs associated with the award issued under RFA-DK-20-509 to Beckman Research Institute/City of Hope is eligible to apply for this single source funding. Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Eligible Applicant Types
Other (see NOFO for details)
Funding Details
- Maximum Award
- $2.2M
- Total Program Funding
- $3.3M
- Expected Number of Awards
- 1
- Cost Sharing Required?
- No
- Funding Instrument
- cooperative_agreement
Key Dates
Posted: May 20, 2026
Application Deadline: September 30, 2026 (35 days remaining)
Agency Contact
Division of Diabetes, Endocrinology and Metabolic Diseases NIDDK_DEM@nih.gov
NIDDK_DEM@nih.govReady to apply?
View the full NOFO and submit your application on Grants.gov